sever
fever
thrombocytopenia
syndrom
sft
emerg
infecti
diseas
caus
novel
member
phleboviru
bunyavirida
increas
sftsv
infect
rais
seriou
concern
east
report
fatal
sftsv
infect
rang
significantli
higher
hemorrhag
fever
caus
hantaviru
although
viru
mainli
transmit
tick
bite
humanhuman
transmiss
effect
therapi
vaccin
avail
yet
mechan
diseas
pathogenesi
poorli
understood
although
previou
studi
reveal
impair
innat
immun
respons
well
inflammatori
cytokin
storm
play
import
role
diseas
knowledg
virusspecif
humor
respons
sftsv
infect
role
pathogenesi
extrem
limit
bcelldepend
immun
regul
antigenpres
cell
apc
follicular
helper
cell
tfh
previou
studi
reveal
dendrit
cell
dc
restrict
antigen
present
alon
could
initi
tfh
cell
program
could
complet
ultim
effector
howev
cooper
mhciiposit
dc
b
cell
could
realiz
optim
effect
tfh
germin
center
gc
bcell
differenti
respons
viral
tfh
along
follicular
dc
repeatedli
undergo
intim
interact
antigenexperienc
b
cell
gc
facilit
bcell
expans
differenti
affin
matur
plasmablast
memori
b
cell
gener
high
affin
therefor
tfh
mainli
resid
gc
lymph
node
ln
spleen
sp
play
pivot
role
product
pathogenspecif
classswitch
neutral
antibodi
number
earlier
studi
demonstr
peripher
tfh
ptfh
cell
exhibit
transcript
phenotyp
similar
lymphoid
tfh
therefor
investig
regulatori
statu
tfh
peripher
blood
sft
patient
addit
cognat
interact
among
immun
cell
regulatori
cytokin
gmcsf
also
requir
gener
mainten
neutral
antibodi
respons
human
mice
model
immatur
b
cell
defici
dcsign
human
dc
express
human
gmcsf
could
correct
defect
igg
respons
antigen
addit
shown
fundament
effector
tfh
cell
humor
shown
critic
marker
tfh
cell
phenotyp
interestingli
proinflammatori
cytokin
essenti
escal
cell
respons
control
persist
viral
nevertheless
role
cytokin
humor
respons
sftsv
infect
poorli
understood
recent
research
show
sftsv
effect
infect
monocyt
interf
signal
pathway
innat
immun
impact
adapt
immun
previou
work
also
show
sftsv
infect
imped
differenti
myeloid
observ
impli
impair
profession
apc
consid
critic
import
apc
establish
adapt
immun
respons
postul
defect
humor
respons
induc
sftsv
infect
current
studi
patient
cohort
examin
dynam
natur
serolog
respons
modul
bcell
subset
myeloid
dc
mdc
ptfh
cell
well
sever
relat
regulatori
cytokin
elucid
statu
bcell
depend
immun
respons
role
pathogenesi
virul
viral
infect
april
octob
patient
admit
nanj
drumtow
hospit
confirm
sftsv
infect
peripher
blood
sampl
patient
deceas
collect
multipl
time
point
rang
day
post
symptom
onset
longitudin
serum
antibodi
respons
np
gn
sft
viru
determin
elisa
western
blot
wb
interestingli
npspecif
igm
igg
complet
absent
deceas
group
symptom
onset
death
fig
b
contrast
npspecif
igm
posit
earli
time
point
symptom
onset
remain
posit
entir
hospit
stay
recov
patient
among
group
patient
serum
antibodi
reach
highest
titer
week
post
symptom
onset
serum
npspecif
igg
fig
c
upper
panel
although
four
ten
convalesc
patient
neg
week
becam
posit
week
post
symptom
onset
manifest
increas
igg
titer
clinic
cours
analyz
serum
antibodi
gn
gc
two
viral
structur
glycoprotein
express
mammalian
cell
purifi
supplementari
fig
accord
serolog
respons
np
titer
gnspecif
igg
recov
patient
manifest
increas
trend
period
symptom
onset
compar
neg
result
deceas
patient
period
fig
confirm
wb
detect
gnigg
week
post
symptom
onset
supplementari
fig
distinct
igm
respons
np
gnspecif
serum
igm
posit
deceas
patient
five
ten
surviv
patient
week
supplementari
fig
becam
undetect
patient
follow
two
week
interestingli
none
patient
sera
react
gc
togeth
absenc
np
gnspecif
igg
deceas
patient
indic
defect
serolog
respons
pathogen
associ
fatal
outcom
fig
f
investig
defect
antibodi
respons
associ
viremia
serum
viral
load
determin
correspond
time
point
quantit
rtpcr
analysi
demonstr
serum
viral
load
surviv
patient
gradual
decreas
acut
phase
sft
becam
undetect
within
day
symptom
onset
fig
strikingli
deceas
patient
maintain
continu
high
level
viremia
symptom
onset
succumb
diseas
viral
load
deceas
group
significantli
higher
surviv
group
period
post
symptom
onset
p
mean
valu
viral
load
deceas
patient
week
respect
compar
surviv
patient
fig
npigg
titer
strong
associ
serum
viral
load
shown
correl
analysi
dynam
data
surviv
deceas
patient
fig
suggest
virusspecif
igg
exert
crucial
effect
viral
clearanc
howev
correl
npigm
titer
viral
load
signific
fig
order
confirm
role
virusspecif
antibodi
clearanc
viru
investig
neutral
activ
gnspecif
antiserum
immun
camel
sera
convalesc
patient
deceas
patient
fig
result
show
sera
gnimmun
camel
convalesc
patient
effect
neutral
sftsv
frnt
valu
respect
comparison
serum
deceas
patient
fail
show
signific
neutral
understand
peripher
bcell
subset
impact
respect
humor
respons
acut
sftsv
infect
analyz
variou
bcell
subtyp
pbmc
flow
cytometri
fig
supplementari
fig
bcell
subset
defin
phenotyp
naiv
memori
mb
plasmablast
pb
margin
zonelik
b
cell
mz
doubleneg
b
cell
composit
total
b
cell
acut
phase
sft
present
fig
other
previous
report
diseas
outcom
impact
number
patient
leukocyt
regul
proport
number
bcell
subset
also
exhibit
high
consist
proport
naiv
b
cell
within
total
peripher
b
cell
deceas
surviv
group
significantli
lower
healthi
control
period
post
symptom
onset
fig
interestingli
mean
weekli
frequenc
naiv
b
cell
deceas
group
dramat
reduc
week
respect
contrast
surviv
group
observ
suggest
overwhelm
activ
exhaust
naiv
b
cell
process
robust
viral
replic
evalu
dynam
two
import
effector
bcell
subset
pb
mb
cell
differenti
naiv
b
cell
fig
e
frequenc
number
pb
mb
subset
surviv
deceas
patient
significantli
higher
healthi
control
although
fraction
mb
total
b
cell
differ
deceas
surviv
group
fraction
pb
deceas
group
increas
significantli
surviv
group
entir
acut
phase
fig
signific
increas
pb
stark
contrast
absenc
serolog
respons
deceas
patient
nevertheless
consist
earlier
report
defect
tcell
particip
led
surg
pb
vsv
mz
b
cell
anoth
rel
small
essenti
subset
significantli
lower
deceas
group
surviv
healthi
group
manifest
declin
progress
sft
fig
frequenc
subset
notabl
increas
diseas
aggrav
deceas
group
reach
total
b
cell
week
compar
surviv
group
fig
investig
compart
fig
demonstr
mean
frequenc
igm
cell
surviv
deceas
healthi
control
group
respect
compar
correspond
frequenc
igg
cell
howev
igg
igm
fraction
cell
show
signific
differ
among
three
group
fig
neg
fraction
cell
deceas
group
significantli
higher
two
group
cell
phenotyp
defin
bcell
precursor
bone
express
subset
could
reflect
degre
matur
bcell
therefor
due
extrem
larg
fraction
b
cell
deceas
patient
infer
dysfunct
prebcel
matur
might
involv
dramat
reduct
matur
naiv
b
cell
phenotyp
character
role
pb
mb
sftsv
infect
examin
immunoglobulin
express
pb
mb
intracellular
stain
igg
igm
fig
pb
mb
percentag
total
b
cell
shown
supplementari
fig
kinet
pb
mb
defin
shown
fig
highli
consist
result
fig
e
pb
surviv
patient
elev
significantli
week
post
symptom
onset
compar
healthi
control
subsequ
decreas
normal
level
week
similar
phenomenon
also
report
ebola
viru
magnitud
pb
expans
deceas
group
markedli
higher
surviv
group
three
week
proport
mb
show
signific
differ
two
group
patient
shown
fig
analysi
immunoglobulin
express
fac
demonstr
signific
differ
classunswitch
pb
among
three
group
fig
howev
classswitch
pb
surviv
patient
exhibit
steadi
elev
week
continu
week
compar
drastic
declin
deceas
patient
even
significantli
lower
healthi
control
fig
interest
larg
fraction
pb
pbmc
observ
deceas
patient
repres
total
pb
week
respect
compar
surviv
group
supplementari
fig
consid
pb
could
secret
immunoglobulin
isotyp
besid
igg
measur
iga
igd
express
pb
fig
found
low
level
igd
iga
fraction
detect
pb
show
signific
differ
two
patient
group
taken
togeth
conclud
rel
larg
fraction
bcell
subset
deceas
patient
secret
igg
igm
igd
iga
isotyp
transcript
profil
pb
investig
analyz
express
three
key
gene
involv
antibodysecret
proceed
antibodysecret
phase
b
cell
significantli
upregul
express
result
show
express
three
gene
pb
significantli
downmodul
deceas
group
fig
illustr
function
regul
asc
sft
patient
perform
elispot
assay
captur
virusspecif
igg
cell
stimul
vitro
use
sampl
three
patient
repres
differ
tempor
phase
clinic
outcom
tlr
agonist
use
nonspecif
sampl
two
surviv
patient
collect
earli
later
phase
acut
sftsv
infect
respect
sampl
patient
collect
one
day
death
pb
two
surviv
patient
deceas
patient
produc
gnspecif
igg
fig
moreov
stimul
combin
gn
protein
produc
specif
igg
secret
surviv
patient
kinet
igm
igg
express
mb
show
surviv
patient
fraction
mb
gradual
declin
mb
significantli
elev
week
post
symptom
onset
fig
middl
lower
panel
indic
later
classswitch
respons
mb
pb
comparison
healthi
control
proport
mb
deceas
patient
show
meaning
regul
understand
role
tfh
bcell
immun
sftsv
defin
ptfh
phenotyp
gate
pbmc
shown
panel
fig
analyz
express
ptfh
vitro
stimul
leukocyt
activ
cocktail
fac
rtpcr
number
ptfh
surviv
deceas
patient
show
robust
increas
week
compar
healthi
control
fig
right
panel
gradual
decreas
follow
two
week
baselin
fig
suggest
ptfh
expans
earli
stage
acut
sftv
infect
associ
recoveri
diseas
moreov
express
ico
surfac
molecul
tfh
migrat
show
signific
differ
among
three
group
fig
left
panel
howev
express
ptfh
deceas
patient
maintain
significantli
higher
level
surviv
patient
healthi
control
fig
right
panel
express
ico
individu
patient
measur
fac
shown
supplementari
fig
fac
analysi
express
ptfh
select
sft
patient
deceas
surviv
demonstr
proport
ptfh
significantli
higher
surviv
patient
deceas
patient
week
post
symptom
onset
fig
left
panel
addit
rtpcr
analysi
also
show
rel
gene
express
sort
ptfh
surviv
patient
significantli
higher
deceas
patient
fig
right
panel
explor
influenc
ptfh
bcell
matur
perform
bcell
helper
assay
place
ptfh
sort
sft
patient
cocultur
autolog
naiv
b
cell
assess
prolifer
express
fac
fig
although
igm
express
show
signific
differ
b
cell
surviv
deceas
patient
greater
prolifer
naiv
b
cell
still
observ
cocultur
autolog
ptfh
surviv
individu
fig
collect
data
indic
impair
tfh
promot
bcell
immun
fatal
sftsv
infect
monocyt
repres
abund
circul
pool
play
critic
role
develop
adapt
immun
respons
present
antigen
provid
costimulatori
signal
b
therefor
analyz
apoptosi
adher
cell
pbmc
consist
week
post
symptom
onset
strikingli
posit
rate
annexin
v
pi
adher
cell
deceas
patient
significantli
higher
surviv
patient
healthi
control
fig
b
indic
monocyt
undergo
sever
apoptosi
earli
stage
sftsv
infect
moreov
vitro
infect
assay
indic
annexin
annexin
vpi
proport
sftsvinfect
mdc
repres
earli
apoptot
cell
late
apoptot
cell
respect
significantli
higher
mock
infect
fig
investig
differenti
function
mdc
fac
patient
blood
sampl
mdc
gate
pbmc
use
lineag
control
fig
sinc
b
cell
major
interfer
select
mdc
robust
differenti
mdc
surviv
deceas
patient
initi
week
sustain
week
post
symptom
onset
fig
supplementari
fig
express
costimulatori
molecul
mdc
week
proport
week
surviv
patient
significantli
higher
deceas
patient
express
show
meaning
differ
patient
group
fig
h
data
suggest
differenti
activ
mdc
surviv
deceas
patient
mainli
due
express
may
impact
antigen
present
function
order
evalu
antigenpresent
function
mdc
sft
viru
infect
isol
mdc
peripher
blood
healthi
donor
perform
allogen
dctcell
cocultur
stimul
assay
use
vitro
infect
fig
j
mdc
infect
sft
viru
prolifer
rate
cell
measur
cfse
tag
level
supernat
significantli
lower
mock
infect
demonstr
mdc
activ
cell
could
inhibit
sft
viru
infect
bcell
antigen
present
cooper
dc
facilit
tfh
differenti
gc
previou
studi
reveal
small
subset
b
cell
mainli
locat
tcell
bcell
border
lymphoid
organ
involv
therefor
indirectli
estim
antigenpres
function
bcell
subset
calcul
express
hladr
peripher
b
cell
fig
express
prove
key
factor
affect
bcell
antigen
deceas
patient
hladr
express
total
b
cell
mb
mz
b
b
cell
significantli
downregul
surviv
patient
week
fig
shown
dynam
b
cell
fig
data
individu
patient
shown
supplementari
fig
meanwhil
proport
cell
express
total
b
cell
mb
mz
b
cell
naiv
b
cell
differ
deceas
surviv
group
fig
c
cytokin
import
matur
function
tfh
dc
therefor
determin
relev
cytokin
sft
patient
sera
use
highli
sensit
milliplex
chip
fig
radar
plot
analysi
present
fig
show
dynam
profil
cytokin
regul
three
week
acut
infect
week
serum
level
increas
dramat
deceas
patient
increas
less
extent
compar
surviv
patient
whose
gmcsf
level
higher
week
show
declin
trend
deceas
group
still
higher
level
surviv
group
except
period
two
repres
inflammatori
cytokin
markedli
elev
deceas
patient
although
nearli
cytokin
measur
deceas
patient
decreas
final
week
compar
previou
two
week
still
maintain
higher
level
surviv
patient
howev
serum
surviv
patient
markedli
elev
accompani
improv
clinic
cours
interestingli
level
sera
nearli
individu
undetect
sinc
sft
persist
public
health
threat
east
asia
almost
time
anoth
novel
phleboviru
term
heartland
viru
hrtv
report
sever
state
america
hrtv
infect
share
mani
common
clinic
characterist
sftsv
includ
high
fatal
rate
hospit
pathogenesi
role
humor
respons
infect
poorli
understood
report
failur
virusspecif
igg
respons
hallmark
fatal
outcom
sft
shown
absenc
serum
igm
igg
specif
np
absenc
igg
specif
gn
deceas
patient
similar
phenomenon
report
ebola
viru
infect
though
virul
viral
absenc
antibodi
respons
sftsv
fatal
case
also
illustr
current
serolog
test
alon
insuffici
diagnosi
sftsv
infect
particularli
sever
case
neutral
assay
confirm
defici
function
humor
respons
fatal
sftsv
infect
implic
potenti
role
gnspecif
antibodi
infect
control
howev
clear
absenc
gc
reactiv
reflect
poor
immunogen
gc
gc
express
nativ
epitop
recogn
serum
antibodi
reactiv
antibodi
current
avail
previou
studi
ebola
viru
infect
report
magnitud
pb
prolifer
close
correl
viru
howev
phenotyp
analysi
pb
two
differ
gate
strategi
show
consist
uniqu
phenomenon
pb
deceas
patient
prolifer
larger
extent
surviv
patient
appar
contrast
weaken
product
virusspecif
antibodi
neg
intracellular
stain
igg
igm
pb
absenc
virusspecif
igg
provid
compel
evid
dysfunct
prolifer
pb
fatal
sft
case
furthermor
inhibit
express
critic
matur
antibodi
product
pb
indic
b
subset
fatal
sftsv
infect
phenotyp
function
pb
function
defect
pb
like
attribut
inhibit
monocyt
dysregul
investig
classswitch
recombin
csr
crucial
establish
effect
antivir
immun
mediat
activationinduc
cytidin
deaminas
aid
matur
b
recent
molecular
mechan
control
csr
studi
pone
et
al
demonstr
bcrsignal
synerg
tlrsignal
induc
aid
immunoglobulin
feldman
et
al
found
chromosom
conform
constant
region
ch
loci
serv
target
csr
regul
cytokin
depend
fashion
matur
b
interestingli
present
studi
observ
signal
pathway
secret
significantli
inhibit
fatal
sftsv
infect
dynam
ptfh
acut
viral
infect
patient
previous
report
despit
limit
data
hiv
siv
infect
anim
found
ptfh
peak
earli
phase
acut
infect
survivor
rapidli
declin
infect
proceed
phenomenon
explain
antigenexperienc
tfh
quickli
migrat
gc
provid
system
help
establish
humor
similar
phenomenon
observ
sivinfect
rhesu
macaqu
earli
loss
splenic
tfh
result
defici
antigenspecif
antibodi
therefor
suggest
earli
expans
tfh
critic
humor
respons
sftsv
infect
control
viral
pathogenesi
although
previou
studi
demonstr
ico
play
critic
role
protect
humor
respons
influenza
ico
ptfh
exhibit
signific
differ
two
sft
patient
group
indic
relat
failur
specif
antibodi
respons
howev
express
crucial
inhibitori
molecul
cell
upregul
maintain
high
level
throughout
entir
diseas
cours
deceas
patient
despit
tcell
exhaust
well
address
chronic
infect
role
acut
viral
infect
especi
regul
subset
poorli
understood
recent
studi
report
high
percentag
cell
express
uniqu
immun
signatur
fatal
ebola
viru
observ
illustr
lethal
sftsv
infect
might
share
uniqu
immun
characterist
ebola
viru
infect
notabl
immunotherapi
shown
effect
safe
control
persist
hcv
infect
therefor
may
serv
potenti
therapeut
target
lethal
sftsv
infect
previou
studi
found
mdc
impair
fatal
consist
recent
report
zhang
et
sinc
monocyt
report
target
cell
investig
apoptot
statu
peripher
monocyt
sft
patient
found
monocyt
underw
sever
apoptosi
necrosi
even
earli
stage
fatal
infect
observ
consist
previou
found
gene
express
monocyt
markedli
inhibit
develop
diseas
sever
signal
report
confer
apoptot
resist
varieti
stress
induc
includ
viru
moreov
significantli
elev
apoptosi
rate
mdc
shown
vitro
infect
assay
confirm
direct
cytopath
effect
sftsv
mdc
phenotyp
function
analysi
reveal
sftsv
infect
could
impair
antigenpres
function
mdc
fact
downmodul
costimulatori
molecul
dc
also
observ
viral
hemorrhag
vitro
studi
demonstr
hiv
infect
frequenc
mdc
approach
condit
contrast
express
mdc
almost
complet
howev
regul
two
costimulatori
molecul
sft
exhibit
entir
distinct
profil
meanwhil
phenotyp
analysi
peripher
b
cell
demonstr
inhibit
express
hladr
memori
mz
b
cell
indirectli
indic
impair
antigenpresent
function
b
cell
transcript
phenotyp
similar
peripher
follicular
b
cell
involv
antigenpres
process
still
poorli
understood
profil
costimulatori
molecul
peripher
b
cell
would
serv
indirect
evid
process
therefor
anim
model
studi
perform
elucid
role
bcell
antigen
present
pathogenesi
sftsv
infect
investig
two
uniqu
characterist
cytokin
regul
observ
fatal
sft
case
one
immunesuppress
cytokin
drastic
elev
earli
phase
follow
subsequ
inflammatori
cytokin
storm
lead
cytokinemedi
organ
damag
shown
suppress
gc
format
affect
tfh
cell
function
part
alter
express
transcript
factor
addit
earlier
studi
show
downregul
mhcii
express
costimulatori
molecul
consist
observ
present
express
gmcsf
absolut
requir
differenti
matur
markedli
downmodul
monocyt
lymphocyt
especi
sever
fatal
observ
strongli
suggest
cytokin
involv
pathogenesi
sftsv
infect
summari
demonstr
complet
absenc
virusspecif
igg
respons
np
gn
associ
fatal
sft
impair
humor
respons
result
global
disrupt
bcell
immun
propos
fatal
sftsv
infect
fig
larg
quantiti
naiv
b
cell
continu
prime
pb
cell
presenc
persist
viremia
howev
due
defect
mdc
matur
result
massiv
monocyt
apoptosi
insuffici
gmcsf
differenti
naiv
cell
tfh
imped
lack
cognat
tfh
mhcii
antigen
present
mdc
b
cell
initi
prime
antigenexperienc
pb
cell
fail
matur
undergo
immunoglobulin
csr
account
complet
absenc
virusspecif
igg
respons
np
gn
deceas
patient
current
studi
also
point
role
np
andor
gnspecif
antibodi
respons
control
viral
pathogenesi
shed
light
potenti
target
vaccin
therapeut
antibodi
develop
clinic
specimen
obtain
sft
patient
admit
nanj
drum
tower
hospit
april
septemb
cohort
consist
deceas
surviv
patient
confirm
sftsv
infect
rtpcr
serum
specimen
store
use
fresh
pbl
util
need
otherwis
cryogen
preserv
use
inform
consent
obtain
subject
accord
declar
helsinki
research
approv
ethic
committe
nanj
drum
tower
hospit
serum
titer
igm
igg
sftsv
nucleocapsid
protein
np
measur
use
commerci
elisa
kit
sinosbio
china
follow
manufactur
instruct
serum
specimen
dilut
serial
concentr
analyz
duplic
human
serum
igg
specif
sftsv
gn
quantit
elisa
express
purifi
gn
dilut
antigenco
buffer
predetermin
concentr
plate
plate
incub
overnight
serum
ad
plate
allow
bind
gn
triplic
h
antihuman
igg
conjug
hrp
abcam
usa
use
secondari
antibodi
optic
densiti
reaction
measur
viral
load
patient
serum
determin
abi
realtim
pcr
system
life
tech
usa
primer
set
forward
primer
revers
primer
probe
rel
gene
express
sort
b
cell
sort
ptfh
determin
flex
realtim
pcr
system
life
tech
usa
use
gene
express
assay
thermo
fisher
usa
accord
manufactur
procedur
quantit
level
mrna
normal
use
cycl
threshold
ct
method
method
compar
valu
amino
acid
sequenc
gn
analyz
tmhmm
server
hydrophob
n
ctermini
gn
gc
remov
solubl
express
truncat
sequenc
gn
expand
amino
acid
residu
wherea
truncat
sequenc
gc
expand
amino
acid
residu
base
genbank
access
number
membran
glycoprotein
polyprotein
sft
viru
express
fragment
construct
kozak
peptid
codon
gn
codon
gc
dna
sequenc
synthes
yclone
ltd
suzhou
china
clone
plasmid
gener
express
vector
transfect
cho
cell
purifi
gn
gc
respect
ninta
bead
smartlifesci
suzhou
china
follow
manufactur
protocol
gn
gc
identifi
western
blot
analysi
antihi
antibodi
santa
cruz
usa
serv
primari
antibodi
dilut
serum
igg
igm
gn
gc
analyz
western
blot
briefli
gn
gc
separ
sdspage
transfer
pvdf
pvdf
stain
overnight
serum
dilut
igg
igm
detect
respect
membran
incub
antihuman
igg
igm
secondari
antibodi
conjug
hrp
abcam
usa
dilut
respect
h
immunoreact
band
igg
igm
detect
hyperfilm
ecl
pierc
usa
fluorchem
system
alpha
innotech
corpor
st
leonardo
ca
usa
respect
sftsv
isol
acut
infect
patient
serum
propag
vero
cell
supernat
dilut
tenfold
serial
dilut
dmem
use
inocul
vero
cell
plate
cell
transfer
glass
cover
slide
h
post
infect
air
dri
fix
permeabil
paraformaldehyd
triton
vero
cell
stain
camel
gnigg
posit
serum
follow
alexa
fluor
rabbit
anticamelid
vhh
antibodi
genscript
china
infecti
viru
titer
calcul
accord
reed
muench
method
aliquot
store
viral
load
quantit
copiesml
rtpcr
camel
prime
gn
prepar
cfa
boost
gn
ifa
everi
two
week
sera
collect
end
week
serum
antibodi
identifi
elisa
wb
analysi
serum
specimen
inactiv
min
neutral
activ
sera
convalesc
sft
patient
post
symptom
onset
fatal
patient
one
day
death
gnimmun
camel
determin
focal
reduct
neutral
test
frnt
number
infect
cell
visual
calcul
use
olympu
fluoview
tokyo
japan
reduct
infect
foci
compar
control
serum
serum
specimen
serial
dilut
mix
equival
volum
viral
aliquot
separ
mixtur
incub
h
transfer
vero
cell
glass
slide
cover
plate
incub
cell
stain
camel
gnigg
posit
serum
follow
alexa
fluor
rabbit
anticamelid
vhh
antibodi
genscript
china
frnt
valu
serum
dilut
determin
graphpad
prism
softwar
usa
pbmc
isol
densiti
gradient
centrifug
use
ficollpaqu
plu
ge
health
bioscienc
sweden
accord
manufactur
protocol
pbmc
cultur
supplement
heatinactiv
fb
plate
h
cultur
medium
gentli
remov
replac
annexinvfitc
pi
work
solut
beyotim
biotechnolog
china
plate
incub
room
temperatur
dark
min
wash
time
bind
buffer
imag
acquir
use
olympu
fluoview
tokyo
japan
pbmc
sft
patient
cultur
supplement
heatinactiv
fb
stimul
leukocyt
activ
cocktail
bd
bioscienc
usa
h
cell
collect
surfac
intracellular
stain
flow
cytometr
analysi
describ
antibodi
reagent
use
flow
cytometri
analysi
purchas
bd
bioscienc
usa
antibodi
group
six
panel
phenotyp
analysi
b
cell
b
pb
mb
cell
c
mdc
e
tfh
f
respect
red
blood
cell
remov
lyse
red
blood
cell
lysi
buffer
antibodi
combin
panel
follow
panel
igdp
panel
b
igdp
panel
c
igmp
panel
igdp
panel
e
panel
f
intracellular
stain
igg
igm
perform
room
temperatur
min
follow
cell
fixat
permeabil
fixperm
buffer
immun
phenotyp
carri
aria
ii
bd
bioscienc
usa
multiparametr
flow
cytomet
data
analyz
use
flowjo
version
treestar
usa
peripher
blood
mononuclear
cell
pbmc
prepar
fresh
heparin
peripher
blood
specimen
densiti
gradient
centrifug
use
ficol
cushion
wash
pbmc
resuspend
pbmcml
medium
gibco
invitrogen
paisley
uk
supplement
streptomycin
glutamin
fetal
bovin
serum
fb
stimul
b
cell
ngml
recombin
human
rh
ad
mabtech
nacka
strand
sweden
vitro
gn
stimul
pbmc
incub
gn
ngml
cell
subsequ
incub
three
day
stimul
cell
wash
prior
plate
steril
multiscreenip
filter
plate
pvdf
membran
millipor
corp
bedford
usa
coat
antihuman
igg
mabtech
nacka
strand
sweden
gn
overnight
number
total
igg
secret
cell
gnspecif
b
cell
determin
well
coat
antihuman
igg
gn
respect
well
antibodi
coat
use
neg
control
plate
wash
steril
pb
block
fb
h
room
temperatur
preactiv
cell
ad
igg
gncoat
well
duplic
respect
incub
h
frequenc
antibodysecret
cell
measur
incub
cell
biotinlabel
antiigg
mab
mabtech
nacka
strand
sweden
follow
horseradish
peroxidas
hrp
conjug
streptavidin
mabtech
nacka
strand
sweden
imag
analysi
carri
autom
elispot
imag
analyz
cellular
technolog
limit
hong
kong
china
ptfh
cell
naiv
b
cell
igd
sort
pbl
patient
healthi
donor
hc
fac
ptfh
cell
stimul
cell
stimul
cocktail
h
complet
wash
label
cfse
naiv
b
cell
use
control
stimul
ptfh
subsequ
cocultur
autolog
naiv
b
cell
ratio
day
flow
cytometri
use
determin
prolifer
igm
express
cocultur
naiv
b
cell
fresh
pbmc
isol
healthi
donor
mdc
isol
use
dendrit
cell
isol
kit
miltenyi
biotec
germani
mdc
cultur
complet
medium
contain
gmcsf
ngml
r
system
stimul
lp
sigmaaldrich
use
infect
portion
mdc
puls
sft
viru
moi
two
hour
cultur
day
apoptot
analysi
cultur
mdc
measur
duplic
flow
cytometri
use
fitcannexin
v
apoptosi
detect
kit
pi
biolegend
china
allomlr
assay
sftsvinfect
uninfect
dc
harvest
mix
cfselabel
allogen
cell
ratio
dc
cell
allogen
mix
lymphocty
reaction
allomlr
dctcell
cocultur
carri
complet
medium
contain
r
system
day
prolifer
cfselabel
cell
allomlr
analyz
flow
cytometri
serum
concentr
select
cytokin
measur
use
map
human
high
sensit
thelper
cell
magnet
bead
panel
merck
millipor
usa
luminex
platform
magpixtm
luminex
austin
usa
analysi
perform
accord
manufactur
instruct
continu
variabl
report
mean
sd
data
analyz
spss
softwar
group
mean
compar
use
anova
independentsampl
test
pearson
correl
test
use
measur
strength
associ
variabl
data
materi
use
articl
avail
author
request
dataset
paper
deposit
open
scienc
framework
access
